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Available online 30 September 2016Background: Osteogenesis imperfecta (OI) is a hereditary connective tissue disease often due to mutations in
genes coding for type 1 collagen. Collagen type 1 is important in the development of the heart and vasculature.
Little is known about the risk of cardiovascular disease (CVD) in OI.
Objective: To investigate the risk of symptomatic CVD in OI.
Design: A Danish nationwide, population-based and register-based longitudinal open cohort study.
Participants: All patients registered with the diagnosis of OI from 1977 to 2013 and a reference population
matched 5:1 to the OI cohort.
Measurements: Sub-hazard ratios for mitral and aortic valve regurgitation, atrial ﬁbrillation and ﬂutter, heart
failure and vascular aneurisms and dissections comparing the OI cohort to the reference population.
Results:We identiﬁed 687 cases with OI (379women) and included 3435 reference persons (1895women). The
SHRwas 6.3 [95% CI: 2.5–15.5] for mitral valve regurgitation, 4.5 [95% CI: 1.4–13.9] for aortic valve regurgitation,
1.7 [95% CI: 1.1–2.8] for atrial ﬁbrillation/ﬂutter, and 2.3 [95% CI: 1.4–3.7] for heart failure. The SHRs were not
increased arterial aneurisms or dissections.
Limitation: Our results were limited by lacking clinical information about phenotype and genotype of the
included patients.
Conclusion:We conﬁrm that patients with OI have an increased risk of CVD compared to the general population.
This held true evenwhen adjusting for factors that are known to contribute to development of these diseases. Our
results suggest that the collagenopathy seen in OI may be part of the pathogenesis of CVD in OI.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND li-
cense (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Osteogenesis imperfecta
Connective tissue disorders
Epidemiology
Register based nationwide
Risk of cardiovascular disease1. Introduction
Osteogenesis imperfecta (OI) or ‘brittle bone disorder’ is a rare sys-
temic connective tissue disorder that is largely caused by mutations in
the genes related to the biosynthesis of collagen type 1 [1]. The clinical
presentation of OI is heterogeneous and ranges from almostearch Unit, Department of
get 10, 6. Sal, 5000 Odense C,
ad), jannie.hald@midt.rm.dk
@aarhus.rm.dk (B.L. Langdahl),
sen@rsyd.dk
ahamsen), kim.brixen@rsyd.dk
land Ltd. This is an open access articlasymptomatic to prenatally lethal. Most patients present with blue
sclera and multiple fractures after little or no precipitating trauma [2].
OI has a population prevalence of 10.6 per 100.000, and a prevalence
at birth of 21.8 per 100.000 [3].
Collagen type 1 is an important constituent of different parts of the
cardiovascular system, including the heart valves, chordae tendineae,
ﬁbrous rings of the heart, the interventricular septum, aorta, and most
other arteries [4,5]. The collagen ﬁbers in the ventricular myocardium
contribute to the tensile stiffness and maintain the architecture of the
myocytes [6]. Two murine OI models, the Aga2 and OIM, in addition
to the bone phenotype also have speciﬁc cardiovascular phenotypes
[6,7]. Furthermore, homozygote OIM mice have lower collagen area
fraction with lower collagen ﬁber number density in the heart [6].
Valvular regurgitation is a frequently reported cardiovascular dis-
ease (CVD) among patients with OI, but most of the current literaturee under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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have reported increased aortic root diameter, increased prevalence of
diastolic dysfunction, and valvulopathies in patients with OI, but most
of the included patients were asymptomatic despite cardiovascular pa-
thology [8]. Furthermore, the studies did not describe the burden of
other, non-structural, diseases of the heart (e.g. atrial ﬁbrillation or is-
chemic heart disease) that could bias the results.
The Framingham Heart Study reported a 39% increased risk of new
onset atrial ﬁbrillation for each 5 mm increase in the left atrium diame-
ter in patients evaluated by echocardiography [9]. In a non-OI popula-
tion, the risk of heart failure is closely associated with ischemic heart
disease and with increasing age [10]. The reduced amount of collagen
type 1 that is seen in OI could result in lower tensile strength and en-
largement of both the atria and the ventricles, thus causing arterial ﬁ-
brillation or ﬂutter and heart failure, independent of other risk factors,
at an earlier age than expected. Casuistic reports have been published
on arterial dissections and vascular aneurisms in OI, but no cross-
sectional or cohort data are currently available [8].
Individual-level data on Danish births, deaths, migration, and all
contacts to the healthcare system are available for research. Discharge
diagnoses for all in-hospital stays and all surgical procedures have
been registered since 1977 and are available through the National Pa-
tient Register (NPR). Since 1994, diagnoses for all emergency depart-
ment and outpatient clinic contacts have also been included in the
NPR [11]. Information on dispensed medical prescriptions has been re-
corded in the Danish National Prescription Register (DNPR) on an indi-
vidual level since 1994 [12]. These registers are linked by a unique
personal identiﬁcation number (CPR) issued to all Danish residents [13].
1.1. Study objectives and hypothesis
We aimed to investigate the risk of CVD in patients with OI com-
pared to the general population using the Danish health registers. We
hypothesized that patients with OIwould have increased risk of CVD, es-
pecially valvulopathies, atrial ﬁbrillation, and cardiac failure as well as
aneurisms and dissections, independent of other risk factors for CVD.
The hypothesis is summarised in Fig. 1.
2. Methods and study population
The present study is part of a large register-based study on OI in Denmark. Results on
mortality and causes of death have been published elsewhere [14].
2.1. Study design
The study is a nationwide population- and register-based open-cohort study that in-
cluded all patients registered with an OI diagnosis in the Danish health registers and a
matched reference population. The participants were followed from 1977 to 2013.
2.2. Data sources
Statistics Denmark Division of Research Services supplied anonymized data (Project
reference number: 704542). The Statistics Denmark Division of Research Services is a
government institution that administers most of the Danish health registers used in
research.
2.3. Study participants
Patients: We included all patients registered in the National Patient Register (NPR)
with an ICD-8 (756.59) or ICD-10 (Q78.0) diagnosis of OI between January 1st 1977 and
December 31st 2012.
Reference population: Five persons, matched to each patient with OI by gender, birth
year andmonth,were randomly selected from theNational Persons Register. To limitmis-
classiﬁcation, the Statistics Denmark Division of Research Services limited the data so that
reference individuals could not be ﬁrst or second degree relatives to the patients with OI,
nor had they later acquired an OI diagnosis.
2.4. Outcomes, variables, and registers
Table 1 shows the different variables, the relevant register and the corresponding di-
agnosis or codes for eachoutcome. The date of diagnosiswas deﬁned as thedate of theﬁrst
entry into the NPR or the date of ﬁrst dispensed prescription of relevant medication.To safeguard patient anonymity, we were not permitted to tabulate outcomes in
any group with fewer than 3 events. For such low frequency events we shall use the
term b3.
2.4.1. Primary outcomes
Information onmitral valve regurgitation, aortic valve regurgitation, atrial ﬁbrillation/
ﬂutter, heart failure, vascular dissections, and aneurisms were extracted from the NPR
through diagnosis or procedure codes.
2.4.2. Secondary outcomes— ischemic CVD
Information on ischemic heart disease or arteriosclerotic disease was extracted as
discharge diagnoses through the NPR. The use of any platelet aggregation inhibitor or
nitroglycerin was taken as an indicator of underlying arteriosclerotic disease, and
extracted information on use of these drugs through the DNPR. Information on any
coronary surgery was extracted from the NPR and interpreted as indicative of ische-
mic heart disease.
2.4.3. Secondary outcomes— risk factors for CVD
Information about diabeteswas extracted through theNPR as ICD-8 or ICD-10diagno-
sis for diabetes, butwe also considered any registration of dispensed anti-diabeticmedica-
tion in the DNPR as indicative of diabetes. Information about dyslipidemia was extracted
through the DNPR as use of any lipid-lowering drugs or through the NPR as any ICD-8
or ICD-10 diagnosis for dyslipidemia. Information about hypertension was extracted
through the DNPR as use of any antihypertensive drugs or through the NPR as any ICD-8
or ICD-10 diagnosis for hypertension. Lastly, information about non-steroidal anti-
inﬂammatory drug (NSAID) use was extracted through the DNPR as a dispensed prescrip-
tion of any NSAID.
2.4.4. Demographic data
Information about time of death was extracted from the Danish Causes of Death
Register. Data on migration were extracted from the CPR register.
2.5. Exposure
As OI is a congenital disease, we deﬁned all identiﬁed patients to be at risk from OI-
related CVD from birth, even if their OI diagnosis was made nominally at a later stage in
life. The participants were followed until death, migration from Denmark, or the end of
the observation period.
2.6. Confounders
2.6.1. Surveillance bias
TheNPR only registers diagnoses related to hospital visits, and not visits to the general
practitioner (GP). PatientswithOI are followed in four adult care centers and twopediatric
care centers in Denmark, and are likely to be registered in the NPR for non-OI related dis-
eases as well. As only some of the cardiovascular conditions included in this study need
hospital care and pre-surgical evaluations usually include ECG, the result may be over-
representation of certain diseases in theOI cohort ifwe only relied on NPR data.We there-
fore deﬁned that a patient had a given disease if they were either registered in the NPR
and/or had been dispensed relevant medication registered in the DNPR (see Table 1).
2.6.2. Register bias— observation period
The registers used in this study do not cover the same period, but have overlapping
years of observation. The NPR covers the period 1977–2013, the DNPR cover 1994–
2013, the National Persons Register was started in 1969 cover all inhabitants of
Denmark. When using registers with a relatively short observation period, we risk
underestimating the number of events. Furthermore, patients may enter the register
some time after being diagnosed with a disease. We have corrected for this potential
bias by deﬁning outcomes equally for all participants and extracting the data from the
same sources. Ibuprofen as a 200 mg tablet is an over-the-counter drug in Denmark and
as such is not registered in the DNPR. We thus risk underestimating the NSAID use in
both groups.
2.6.3. Bias by pre-existing CVDs and risk factors for CVDs
Other CVDs and risk factors for CVDs, which are less likely to be inﬂuenced by the
amount or quality of the available collagen type 1 (e.g. ischemic heart disease), could in-
ﬂuence our results. Fig. 1 shows the relationships between the variables included in our
study. We ran both an unadjusted model to describe the overall excess risk in patients
with OI and an adjusted model to estimate the excess risk directly attributable to OI
after correcting for differences in clinical risk factor proﬁle.
2.6.4. Competing risks bias
We have previously shown that patients with OI have increased risk of premature
death compared to the reference population (unpublished but accepted for publication
JBMR). The competing risk of death may result in a lower number of outcome events in
the OI cohort. We therefore used the Fine and Gray [15] competing risk regression to
calculate the SHR between the OI cohort and the reference population.
Table 1
Variables and sources.
Disease/condition Deﬁnition Data
source
Years of register
coverage
Codes Variables
Endpoints
Mitral valve regurgitation Relevant ICD-8 or ICD-10 diagnosis
codes OR surgical codes
NPR 1977–2013 ICD-10 & ICD-8 I352, 42411, 39591, 39692
Surgery codes KFK, 31119, 31129, 31130
Aortic valve regurgitation Relevant ICD-8 or 10 diagnosis
codes OR surgical codes
NPR 1977–2013 ICD-10 & ICD-8 I340, 39491, 42401, 39692, 39693
Surgical codes KFMb, 31259, 31260, 31268, 31269
Heart failure Relevant ICD-8 or 10 diagnosis codes NPR 1977–2013 ICD-10 & ICD-8 I50, 4270b, 4271b, 78239, 42899
Arterial ﬁbrillation or ﬂutter Relevant ICD-8 or 10 diagnosis codes NPR 1977–2013 ICD-10 & ICD-8 I48b, 42791, 42792, 42793, 42794
Vascular dissection or aneurism Relevant ICD-8 or 10 diagnosis
codes OR surgical codes
NPR 1977–2013 ICD-10 & ICD-8 I254, 60, I670, I671, I690, I71, I72,
I790, 43000, 43001, 43090, 43701,
43791, 441b, 442b, 09309, 09492
Surgical codes Surgery to aorta and main branches:
KFC KPAG KPAN KPAP KPAQ KPBG
KPCG KPDG KPEG KPFG 865 866 867
Surgery to cerebral vessels: KAAC KAAL
01900 01940 01950
Surgery to small vessels: KPCH KPCN
KPCQ KPDH KPDN KPDP KPDQ KPEH
KPEN KPEQ KPFH KPFN KPFP KPFQ
KPG 860b 861b 862b 863b 864b 868b
869b 870b 871b(excluding 87150)
Risk factors for CVD and other cardiovascular diseases
Hypertension Relevant ICD-8 or ICD-10 diagnosis
codes OR use of any antihypertensive
drugs
NPR DNPR ICD-8 or ICD-10 I10 40b
ATC C02, C03, C04, C07a, C08, C09
Arteriosclerotic disease Relevant ICD-8 or ICD-10 diagnosis
codes OR relevant operation codes
OR use of platelet inhibitors
NPR DNPR ICD-8 or ICD-10 I20 I21 I22 I23 I24 I251 I258 I252
I253 I255 I256 412b 413b 414b 410b
I64 I65 I66 I70 I739 440b
Surgical codes KFN KPBH KPAH 30350 30354
30359 30009 30019 30020 30029
30039 30049 30059 30069 30079
30089 30109 30119 30120 30129
30139 20149 30159 30160 30169
30179 30189 30199 30200 30240
30241 30245 30250 30280 30390
ATC B01AC C01D
Dyslipidemia Relevant ICD-8 or ICD-10 diagnosis
codes OR use of any lipid lowering drugs
NPR DNPR LPR E78 27201 27200 27900 27201
ATC C10
Diabetes Relevant ICD-8 or ICD-10 diagnosis
codes OR use of any anti-diabetic drugs
NPR DNPR 1977–2013 ICD-10 & ICD-8 E10, E11, E12, E13, E14, 249b, 250b
ATC A10
Non-steroidal anti-inﬂammatory drug use Use of NSAID DNPR ATC M01A
The table shows the registers and codes used for each outcome. ICD= International Classiﬁcation of Diseases (World Health Organization), NPR=National Patient Register, CVD= car-
diovascular diseases, ATC=Anatomical Therapeutic Chemical Classiﬁcation, DNPR=Danish National Prescription Register. Surgery has been part of theNPR since 1977, ﬁrst using a Dan-
ish operation and treatment classiﬁcation manual published by the Danish Health Authority until 1995, and thereafter using the Nordic Classiﬁcation of Surgical Procedures.
a Without simultaneous use of anticoagulative drugs.
b Including all following chapters.
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To limit immortal time bias, i.e. where patients emigrate from Denmark and may be
diagnosed with one of the outcomes but are not registered in the Danish health registers,
we censored any participants who had emigrated.
2.7. Statistical analysis
All statistical analyses were done using Stata® 14.1 (StataCorp, USA). We present the
cumulative risk of having a given outcome over time and estimating the time to an event
per participant. Data are presented as mean [±1 SD], median [interquartile range, or
range], number of events and percent of the population, as appropriate. Sub-hazard ratios
(SHRs) are presented as the SHR between the OI cohort and the reference population,
accepting a signiﬁcant SHR if the 95% CI did not include the value of 1.00.
To evaluate the between-group SHR, we ﬁtted Fine and Gray [15] semi-parametric
competing risk regression models for each primary outcome. We pre-speciﬁed subanalysis
by gender.
We adjusted models for preselected variables as described in Fig. 1 on the rationale
that these variableswere not associatedwithOI itself, but increased the risk of the primary
outcomes. The unadjustedmodel will show any increased risk of CVD in theOI cohort. The
adjusted model – taking other causes of the outcomes into account – will show any in-
creased risk of CVD that can be attributed statistically to OI itself.
We adjusted the SHR estimations for mitral regurgitation and atrial ﬁbrillation or
ﬂutter for 1) pre-existing use of platelet aggregation inhibitors, 2) pre-existing use of
nitroglycerin agents, 3) any pre-existing diagnosis of acute myocardial infarction or
arteriosclerosis, and 4) any pre-existing procedures to the coronary arteries(percutaneous coronary interventions) AND/OR coronary by-pass surgery — thus
adjusting the analysis for ischemic heart disease. We accept that we corrected for
proxy measures for ischemic heart disease, but wanted an adjusted model to take
into account high-risk patients that may have had silent ischemic cardiovascular
disease or silent ischemic myocardial infarctions — where no information about
their ischemic heart disease would have been registered in the NPR.
We adjusted the models for evaluating the SHR for heart failure for 1) the same
variables as above, and 2) pre-existing diagnosis of atrial ﬁbrillations or ﬂutter, thus
adjusting for any increased risk of heart failure due to atrial arrhythmia and ischemic
heart disease.
The models evaluating the SHR for vascular aneurisms and dissections were adjusted
for 1) any pre-existing use of antihypertensive drugs, and 2) pre-existing diagnosis of di-
abetesmellitus AND/OR any use of antidiuretic drugs, thus adjusting for the increased risk
of aneurisms and vascular dissections in hypertension and the decreased risk seen in pa-
tients with diabetes.
The assumption of proportional sub-hazards was tested by introducing a time-varying
coefﬁcient, observing the interaction with time with the grouping variable (OI or reference
population), accepting that if the proportional sub-hazards assumption held, then the coefﬁ-
cients would be constant with time, and the time interactions should not be statistically
signiﬁcant.
We used Persons chi-squared to test for differences in categorical variables between
the two populations. We corrected for multiple testing using the Bonferroni correction
and accepted a p-value of below 0.003 as signiﬁcant (as we tested 16 between-group dif-
ferences in prevalence of different CVDs, surgical treatment of CVDs or risk factors for
CVDs).
Fig. 1. Theoretical relationship between risk factors for the cardiovascular outcomes included in this study and osteogenesis imperfecta (OI) We hypothesized that patients with OI have
increased risk of heart failure, atrial ﬁbrillation or ﬂutter (AFLU/AFIB), vascular dissections, and mitral and aortic valve regurgitation (solid lines). The dashed lines show the various risk
factors related to each cardiovascular outcome. OI causes frequent fractures (that may lead to immobilization) and hypermobility, both of which may increase the use of NSAIDs, which
increases the risk of ischemic heart disease. Immobilization can increase the risk of diabetes, dyslipidemia, and hypertension, all of which increase the risk of ischemic heart disease, which
in turn increases the risk of heart failure,mitral regurgitation, andAFLU/AFLI. Atrial arrhythmia also increases the risk of heart failure. Hypertension increases the risk of vascular dissection,
while prevalence of diabetes decreases this risk.Male gender and increasing age are also risk factors for hypertension, ischemic heart disease, diabetes, dyslipidemia, and the cardiovascular
outcomes in this study.We thus adjusted our analysis for: 1) gender and age bymatching the two cohorts, 2) heart failure for pre-existing ischemic heart disease and AFLU/AFLI, 3) AFLU/
AFLI for pre-existing ischemic heart disease, 4) vascular dissections and aneurisms for pre-existing hypertension and diabetes, 5)mitral valve regurgitation for pre-existing ischemic heart
disease. Smoking is a risk factor for almost all the above, but data on smoking habits was not available and could not be included in themodel. Some cardiovascular diseases show familial
clustering, and OI is a hereditary disease. However, we had no information about the family units in our OI cohort and could not control for familial clustering in the models.
253L. Folkestad et al. / International Journal of Cardiology 225 (2016) 250–2572.8. Ethical considerations
The study was approved by the Danish Data Protection Agency. The investigators
were blinded to the identity of the patients and the reference population. The study was
not a clinical trial and thus did not require ethics committee approval according to Danish
law. To ensure participant conﬁdentiality, results are not shown if the number of partici-
pants in a subgroupwas under three. The studywas approved by Statistics Denmark (pro-
ject 704542).3. Results
We identiﬁed 687 patients (379 women), of whom 112 died during
the observation period, and 3435 persons (1895 women) in the refer-
ence population, of whom 257 died during the observation period.
The median follow-up for the primary outcomes was 23,588 [range:
23,497–23,645] person years in the OI group and 120,005 [range:
119,931–120,104] person years in the reference population. The base-
line characteristics are summarized in Table 2.Table 2
Baseline characteristics.
OI cohort
Number of participants [N] 687
Female participants [N, %] 379 (55%)
Median age when entered into registers 0 [IQR: 0–65
Median age at end of observation 33.6 [IQR: 15
Median follow-up time per primary outcome 23,588 [rang
The table shows the baseline characteristics of the two populations. IQR = interquartile range3.1. Secondary outcomes (other CVDs and risk factors for CVD)
Table 3 shows the number of patients registeredwith each of the in-
cluded CVDs and risk factors for the CVDs included in this study. The OI
cohort had an increased use of antihypertensive drugs and a higher pro-
portion of patients registered with a hypertensive discharge diagnosis
in the NPR compared to the reference population (28.1% vs. 21.6%,
p b 0.001). Patients with OI had increased use of prescription NSAIDs
compared to the reference population (57% vs. 47%, p b 0.001). There
was no increased prevalence of ischemic heart disease in the OI cohort.3.2. Main outcomes
Table 4 shows the number of events in each group and the sub-
hazard ratios between the OI cohort and the reference population for
both the adjusted and unadjusted models, for all participants and by
gender. The cumulative incidence function, deﬁned as the probabilityReference population
3435
1895 (55%)
.4] 0 [IQR: 0–65.4]
.5–53.0] 33.5 [IQR: 17.1–53.8]
e: 23,497–23,645] 120,005 [range: 119,931–120,104]
.
Table 3
Cardiovascular risk factors and other cardiovascular diseases.
Data source OI cohort [N (%)] Reference population [N (%)] p-Value
Ischemic CVD Composite 76 (11.0) 368 (10.7) 0.79
ACS NPR 31 (4.5) 143 (4.2) 0.68
Arteriosclerosis NPR 18 (2.6) 81 (2.4) 0.68
NTG usage DNPR 27 (3.8) 118 (3.4) 0.65
Platelet aggregation inhibitors DNPR 61 (8.9) 325 (9.5) 0.63
Coronary artery procedures NPR 5 (0.7) 42 (1.2) 0.27
Diabetes Composite 38 (5.5) 147 (4.3) 0.15
Diabetes treatment, any DNPR 28 (4.1) 132 (3.8) 0.77
Diabetes NPR 24 (3.5) 95 (2.8) 0.3
Hypertension Composite 193 (28.1) 742 (21.6) b0.001
Antihypertensive use, any DNPR 190 (27.7) 730 (21.3) b0.001
Hypertension NPR 74 (10.8) 207 (6.0) b0.001
Dyslipidemia Composite 73 (10.6) 356 (10.4) 0.84
Dyslipidemia NPR 18 (2.6) 77 (2.2) 0.55
Lipid-lowering drugs DNPR 71 (10.3) 353 (10.3) 0.96
Other risk factors
NSAID DNPR 389 (56.6) 1627 (47.2) b0.001
The table shows the number of participants found through the different data sources with each diagnosis. The ﬁrst event registered was counted for each participant. Composite = the
combination of NPR and DNPR data, NPR = National Patient Register, DNPR = Danish National Prescription Register, ACS = acute coronary syndrome, NTG = nitroglycerin, NSAID =
non-steroidal anti-inﬂammatory drug use.
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each main outcome in Fig. 2.3.2.1. Mitral valve regurgitation
Eleven patients (1.6%) with OI (median age at diagnosis 63 years,
IQR 40–69) and 8 patients (0.2%) (median age at diagnosis 75 years,
IQR 65–89) in the reference population were registered with a mitral
valve regurgitation diagnosis. The unadjusted SHR between the two
groups were 6.3 [95% CI 2.5–15.5] p b 0.001. After adjusting for prior is-
chemic CVD the adjusted SHR was 6.7 [95% CI 2.8–16.2] p b 0.001. The
cumulative incidence increased from the age of 60 years. Signiﬁcantly
more patients in the OI cohort had been surgically treated for mitral
valve regurgitation than in the reference population (4 (0.6%) vs. b3
(b0.1%), p b 0.001) by the end of the observation period.Table 4
Primary outcomes, number of patients and sub-hazard ratios (SHRs).
Age at debut
OI (IQR)
Age at debut ref.
pop (IQR)
Obs. time OI
cohort [years]
Obs.
pop.
Total population
Mitral valve regurgitation 63 (40–69) 75 (65–80) 23,588 120,0
Aortic valve regurgitation 42 (33–69) 56 (42–68) 23,645 120,1
Atrial ﬁbrillation or ﬂutter 64 (50–71) 70 (62–78) 23,518 119,8
Heart failure 58 (44–69) 76 (62–83) 23,497 119,8
Vascular aneurisms or dissections 55 (44–69) 76 (62–83) 23,592 120,0
Men
Mitral valve regurgitation 65 (40–69) TFE 9535 48,79
Aortic valve regurgitation TFE TFE 9562 48,98
Atrial ﬁbrillation or ﬂutter 63 (53–70) 64 (60–70) 9457 48,82
Heart failure 62 (58–70) 68 (59–82) 9506 48,91
Vascular aneurisms or dissections 51 (29–56) 70 (64–76) 9516 48,97
Women
Mitral valve
regurgitation
58 (47–66) 75 (63–84) 14,053 71,12
Aortic valve regurgitation TFE TFE 14,084 71,12
Atrial ﬁbrillation or ﬂutter 64 (37–71) 76 (69–80) 14,062 70,89
Heart failure 52 (39–67) 77 (68–83) 13,991 70,96
Vascular aneurisms or dissections TFE 57 (48–63) 14,077 711,0
The table shows the observation period for each outcome, the number of participants registered
not present total numbers when under 3 i.e. TFE = too few events.
a Corrected for ischemic CVD.
b Corrected for ischemic CVD and atrial ﬂutter or ﬁbrillation.
c Corrected for hypertension and diabetes.3.2.2. Aortic valve regurgitation
Six patients (0.9%) with OI (median age at diagnosis 42 years, IQR
33–69) and 6 patients (0.02%) in the reference population (median
age at diagnosis 56 years, IQR 42–68) were registered with an aortic
valve regurgitation diagnosis (unadjusted SHR 4.5 [95% CI 1.4–13.9]
p = 0.01). Proportionally more patients with OI than participants in
the reference population were surgically treated for aortic valve regur-
gitation, but after correcting for multiple testing, this difference was
not statistically signiﬁcant (4 (0.6%) vs. 5 (0.2%), p = 0.025).3.2.3. Atrial ﬁbrillation or atrial ﬂutter
There was an increased risk of atrial ﬁbrillation or ﬂutter when com-
paring patients with OI to the reference population (adjusted SHR of 1.6
[95% CI 1.0–2.7], p = 0.049). The median age at diagnosis was 64 yearstime ref.
[years]
OI cohort
[N (%)]
Ref. pop.
[N (%)]
Unadjusted
SHR
p-Value Adjusted SHR p-Value
91 11 (1.6) 8 (0.2) 6.3 [2.5–15.5] b0.001 6.7 [2.8–16.2]a b0.001
04 6 (0.9) 6 (0.2) 4.5 [1.4–13.9] 0.010 – –
05 23 (3.4) 61 (1.8) 1.7 [1.1–2.8] 0.030 1.6 [1.0–2.7]a 0.049
73 28 (4.1) 56 (1.6) 2.3 [1.4–3.7] 0.001 2.4 [1.5–3.8]b b0.001
05 TFE 29 (0.8) 1.4 [0.6–3.0] 0.376 1.4 [0.7–3.0]c 0.376
1 5 (1.6) TFE 10.7 [2.0–55.7] 0.026 22.2 [8.3–59.3]a b0.001
0 3 (1.0) 3 (0.2) 4.2 [0.9–21.0] 0.078 –
3 12 (3.9) 24 (1.6) 2.2 [1.1–4.4] 0.022 2.3 [1.1–4.6]a 0.022
3 10 (3.3) 21 (1.4) 2.0 [0.9–4.3] 0.410 2.4 [1.2–5.0]b 0.015
9 TFE 14 (0.9) 2.2[0.9–5.6] 0.094 2.2 [0.9–5.7]c 0.094
1 5 (1.3) TFE 4.7 [1.5–14.5] 0.005 4.2 [1.4–12.4]a 0.011
4 3 (0.8) 3 (0.2) 4.7 [1.5–14.5] 0.062 –
1 11 (2.9) 37 (2.0) 1.4 [0.7–2.8] 0.341 1.3 [0.6–2.6]a 0.473
0 18 (4.8) 35 (1.9) 2.3 [1.2–4.3] 0.012 2.5 [1.4–4.6]b 0.003
26 TFE 15 (0.8) 0.6 [0.1–2.6] 0.509 0.6 [0.1–2.7]c 0.522
with an outcome and the between-group SHR. To ensure participant conﬁdentiality,we do
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Fig. 2. The between-group cumulative incidence function — as predicted by the between-group, unadjusted Fine and Gray competing risk regression models. The cumulative incidence
function was deﬁned as the probability that a particular outcome had occurred before a given time and can be considered as the difference in risk of having the event in question. The
OI cohort is depicted as a dashed line, and the reference population as a solid line.
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population. Correcting for ischemic heart disease did not inﬂuence the
SHR. Analyzing the results in women alone, SHR was not signiﬁcantly
above 1.0 in women with OI compared with women in the reference
population.
3.2.4. Heart failure
The median age at diagnosis was 58 years (IQR 44–69) in the OI co-
hort and 76 years (IQR 62–83) in the reference population. The unad-
justed between-group SHR was 2.3 [95% CI 1.4–3.7] After adjusting for
confounders for heart failure, there was a signiﬁcant higher prevalence
of heart failure in the total OI population, with a between-group SHR of
2.4 [95% CI 1.5–3.8], p b 0.001. Four percent of the women in the OI
cohort and 1.7% of the reference population were registered with a
heart failure diagnosis in the NPR (adjusted SHR 2.5 [95% CI 1.4–4.6],
p = 0.003). The same ﬁgures for men were 1.0% vs. 0.2% (adjusted
SHR 2.4 [95% CI 1.2–5.0], p = 0.015).
3.2.5. Vascular dissections and aneurisms
Nine patients with OI (1.3%) and 29 (0.8%) of the reference popula-
tion were registered with a vascular dissection or aneurism diagnosis
in the NPR. Also, there were no signiﬁcant differences between the
two groups regarding the prevalence of surgery on peripheral arteries,
aorta and its main branches, or cerebral aneurisms.
4. Discussion
Wepresent data from anationwide, register-based cohort study that
includes all patients registeredwith anOI diagnosis in theDanish health
registers between 1977 and 2013, together with a matched reference
population. This is, to our knowledge, the largest cohort study oncardiovascular disease in OI and the ﬁrst based on registry data from a
uniform, tax ﬁnanced, public healthcare system. The study includes a
median of 23,588 (range: 23,497–23,645) person years in the OI
group. We found increased risk of mitral valve regurgitation, aortic
valve regurgitation, heart failure, and arterial ﬁbrillation or ﬂutter in pa-
tients with OI, even after correcting for known risk factors for these
diseases.
4.1. Valvular CVD in OI
In our study, the frequency of mitral and aortic valve regurgitation
was low. Only 1.3% of the women and 1.6% of the men in the OI cohort
were registered with a mitral valve regurgitation diagnosis, and less
than 1% of the total OI population was registered with aortic valve re-
gurgitation. In a Norwegian cross-sectional echocardiography study of
99 adults with OI and a mean age of 43.9 years [±12.3], Radunovic
et al. [16] found that 57.5% of patients had mild mitral regurgitation
and 7.1%hadmoderatemitral regurgitation,while 10.1% hadmild aortic
valve regurgitation and 10.1% had moderate aortic valve regurgitation.
In an Italian cross-sectional study, Migliaccio et al. [17] included 40
clinically asymptomatic NYHA class I patients with OI in a cross-
sectional echocardiography study, and found that 38 patients had val-
vular regurgitation without speciﬁc valvular structural alterations. The
lower numbers seen in our study could be due to some of the valvular
pathologies being asymptomatic and thus not diagnosed. Secondly, we
included the total population of registered OI patients — thus also
including children. Our ﬁndings are more in line with the results of a
Canadian cross-sectional echocardiography study that included 109
patients with OI with a mean age of 27 years (range 1–75), where the
authors reported clinically discernible valvular dysfunction in 4 (3.7%)
patients [18].
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We saw an increased cumulative incidence of heart failure in pa-
tients with OI from the age of 40 years (Fig. 2), and 4.1% of the patients
were registered with a heart failure diagnosis in the NPR. Migliaccio
et al. [17] found similar ejection fraction between patients with OI and
healthy controls, but reported that 95% of OI patients had diastolic
dysfunction. Radunovic et al. [19] found that despite the left ventricle
systolic and diastolic functions being within normal range, they were
signiﬁcantly lower in the OI population than in the control individuals.
The increased SHR was statistically independent of ischemic heart
disease.
4.3. Atrial arrhythmias in OI
Relatively more patients with OI than controls were registered with
an atrial ﬁbrillation or ﬂutter diagnosis in our cohort. This increased risk
was only seen inmen. Radunovic et al. [19] found no patientswith atrial
ﬁbrillation or ﬂutter in their cohort of 99 patients with OI.
Atrial ﬁbrillation and ﬂutter may be under-diagnosed in the Danish
health registers, as the conditions can go undetected. The positive pre-
dictive value of atrial ﬁbrillation and/or atrial ﬂutter diagnosis in the
NPR has been reported to be 92.6% (95% CI: 88.8–95.2%) [20], but no in-
formation about the sensitivity of the NPR has been reported (i.e. the %
of patients with atrial ﬁbrillation who are registered in the NPR) [21]. In
a British epidemiological study of arterial ﬁbrillation, 2.0% [95% CI 1.6–
2.4] of participants randomly selected from the general population
were diagnosed with atrial ﬁbrillation [22]. This is comparable to the
1.8% patients with an atrial ﬁbrillation or ﬂutter diagnosis found in the
control population.
4.4. Arterial dissection or aneurism in OI
Seven men and fewer than 3 women had a vascular dissection or
arterial aneurism during the observation period. A literature review
including 70 patients with OI from 63 case reports or small case series,
showed that 13 patients were described with aortic dissection or aneu-
rism [8]. The reason for this difference can partly be explained by publi-
cation bias of the case reports. No cross-sectional studies have
systematically evaluated the incidence of vascular abnormalities in OI.
Hortop et al. [18] found that the ratio of the observed to the expected
aortic root diameter based on weight and age was above 127% (indica-
tive of aortic root dilatation) in 12.1% of the participants.
4.5. Study limitations
Our study was observational and based on register data and thus
limited to the available data on diagnosis, surgical codes, and dispensed
prescriptions. No information about clinical variables such as height,
weight, smoking habits, alcohol consumption, or compliance to medi-
cine is available in the Danish health registers. In a Canadian study in-
cluding 14 children with OI, none of the patients reached the daily
recommendation of physical activity [23]. In the Norwegian cross-
sectional study of cardiovascular morbidity in patients with OI, 41% of
the patients were current or previous smokers. More OI patients than
participants in the reference population had a dispensed prescription
for NSAID (56.6% vs. 47.2%, p-value b0.001). It is possible that patients
with OI more often than the reference population will use prescription
NSAID. Low dose NSAID is sold over the counter in Denmark and will
not show up in the DNPR. Several observational studies using Danish
health registries have shown increased risk of adverse cardiovascular ef-
fects associatedwithNSAID [24]. However, no differenceswere found in
the proportion of diabetes, dyslipidemia, or ischemic heart disease be-
tween the two cohorts. There could furthermore be an increased risk
of certain CVDs in the OI cohort due to factors that are undetectable
through the NPR registers. We had no information on what had led totheOI diagnosis, and therewas no knowledge about the positive predic-
tive value or the sensitivity of an OI diagnosis in the NPR. It is also con-
ceivable that the diagnostic barrier for asymptomatic heart disease
could be somewhat lower in patients with OI as they would be assessed
at regular intervals by specialist centers for rare diseases or bone
specialists.
4.6. Study strengths
This is, to our knowledge, the ﬁrst nationwide, register-based cohort
study focused on cardiovascular disease in OI. The data collected for this
study came from a uniform and nationwide tax-ﬁnanced health care
system. The national registers were designed for management and
ﬁnancial control and thus have complete long-term follow-up. The
coverage of the NPR is above 99% of all hospital contacts and 95% of all
surgical procedures [11]. Studies have shown good concordance in
register-based studies and questionnaire studies on drug use, using
the DNPR [12]. Lastly the age- and gender-matched reference group of
randomly selected participants from the general population strength-
ened the study.
5. Conclusion
We conﬁrm that patients with osteogenesis imperfecta have in-
creased risk of cardiovascular disease. From the age of 50 years there
was a signiﬁcant increase in cumulative incidence for heart failure, mi-
tral valve regurgitation, aortic valve regurgitation, and atrial ﬁbrillation
or ﬂutter in the OI cohort. The sub-hazard ratio remained higher in the
OI cohort after adjusting for diseases that can cause valvulopathy, atrial
arrhythmia, and heart failure, which is in line with the idea that the de-
creased collagen type 1 found in OI can cause these diseases. We found
no increased risk of vascular dissections, but larger systematic cross-
sectional studies including a reference population are needed to further
evaluate the risk of vascular abnormalities in patients with OI. We rec-
ommend that the follow-up of patients with OI includes ECG in adults
and an evaluation by echocardiography from the age of 50 years of age.
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